Sign In
Buy CABA
$3.58
-0.100 (-2.72%)
At Close: Jun 03, 2026
Cabaletta Bio to Present at the Jefferies Healthcare Conference
08:00am, Thursday, 27'th May 2021
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pa
Cabaletta Bio's Cell Therapy In Skin Blistering Disorder Shows Favorable Safety Profile
01:17pm, Monday, 03'rd May 2021
Cabaletta Bio Inc (NASDAQ: CABA) has announced acute safety data from the first dose cohort of the ongoing DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus Vulgaris (mPV). I
Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
07:05am, Monday, 03'rd May 2021
– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of
Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial
07:00am, Monday, 03'rd May 2021
– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 –
Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
07:30am, Tuesday, 16'th Mar 2021
PHILADELPHIA, March 16, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for
5 Stocks for Solid Returns as Analysts Initiate Coverage
11:22am, Monday, 01'st Feb 2021
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Cabaletta Bio (CABA), Alto (PEIX), Ribbon (RBBN) and Software Acquisiti
Cabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young Biotech
11:40am, Wednesday, 20'th Jan 2021
Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases. Cabaletta has 3 potential therapeutics from its the
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune di
Cabaletta Bio to Participate in Upcoming December Investor Conferences
08:00am, Monday, 23'rd Nov 2020
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p
Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update
07:30am, Tuesday, 10'th Nov 2020
PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p
Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update
11:30am, Thursday, 06'th Aug 2020
PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p
Cabaletta Bio to Present at Multiple August Investor Conferences
12:00pm, Monday, 03'rd Aug 2020
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p
Celyad Oncology annoncera prochainement les résultats financiers du premier semestre 2020 et tiendra une conférence téléphonique
12:00am, Monday, 03'rd Aug 2020
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq : CYAD), une société de biotechnologie de stade
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
11:42am, Friday, 24'th Jul 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Morgan Stanley Reaffirms Their Buy Rating on Cabaletta Bio (CABA) - Markets
07:28pm, Wednesday, 15'th Jul 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Cabaletta Bio (CABA – Research
